Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
5.41
+0.15 (2.85%)
At close: Oct 26, 2026, 4:00 PM EDT
5.32
-0.09 (-1.66%)
After-hours: Oct 26, 2026, 4:06 PM EDT
Valneva SE Market Cap
Valneva SE has a market cap or net worth of $513.03 million as of October 26, 2026. Its market cap has decreased by 36.80% in one year.
Market Cap
513.03M
Enterprise Value
612.24M
1-Year Change
-36.80%
Global Rank
n/a
Country Rank
n/a
Category
ChartMarket Cap Chart
Since the IPO on May 6, 2021, Valneva SE's market cap has decreased from $1.29B to $513.03M, a decrease of -60.31%. That is a compound annual growth rate of -15.53%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 26, 2026 | 513.03M | -31.97% |
| Dec 31, 2025 | 754.16M | 107.47% |
| Dec 31, 2024 | 363.50M | -49.80% |
| Dec 29, 2023 | 724.08M | -21.32% |
| Dec 30, 2022 | 920.30M | -68.57% |
| Dec 31, 2021 | 2.93B | 126.51% |
| May 6, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Bright Minds Biosciences | 516.67M |
| Entera Bio | 507.85M |
| CytomX Therapeutics | 505.53M |
| Oculis Holding AG | 487.68M |
| Indaptus Therapeutics | 485.32M |
| Arvinas | 477.32M |
| Monopar Therapeutics | 474.21M |
| Neurogene | 471.27M |